Couple help NHS mark 75 years of cataract surgery
The NHS is celebrating 75 years of cataract surgery, an operation which helps restore vision.
The operation involves removing a lens - a small transparent disc inside the eye - that has become cloudy and replacing it with one made out of acrylic plastic.
Without the operation, the cloudy vision can lead to blurry vision and eventually blindness. Roughly half of those over the age of 60 have some degree of cataracts.
Since it was first offered at St Thomas' Hospital in 1950, nearly one billion cataract surgeries are estimated to have taken place across the world.
One couple from south-east London who have undertaken the procedure is John and Freda McBean.
"I am already feeling better and can see more brightness than I could see before," said Mr McBean, a retired deputy teacher from Chislehurst.
About 10 years ago, he tore his retina and during the procedure to fix it, the surgeon noticed a cataract was starting to form.
Over the last five years, Mr McBean's vision deteriorated leading him to have cataract surgery on his left eye in February to remove the cloudy lens.
He said he was not nervous as his wife had the operation on both eyes last year.
Mrs McBean, 72, said her vision was now excellent, and that she only needed reading glasses for very fine print.
The retired primary school teacher said: "The surgery went beautifully and the experience was unbelievable."
Speaking of his own procedure, Mr McBean said: "I couldn't believe it when I was told I was one of the patients getting surgery around the anniversary.
"I feel like I know the surgery so I wasn't nervous."
He added: "It was amazing and I am absolutely in awe of the team.
"It's amazing that over the course of my lifetime this operation has been finessed, and it's nice to be a part of the history of the hospital."
Sir Harold, the creator of the procedure, made his medical breakthrough after treating a Spitfire pilot who had splinters of acrylic in his eye.
He noticed that unlike most other foreign material, the eye did not reject this type of plastic.
At the time, Sir Harold's invention was considered radical and was initially resisted by much of the medical profession - but over time it has become the most common eye operation in the world.
Today, the surgery takes only 15 to 30 minutes per eye, and patients are discharged within hours.
To celebrate 75 years since its invention, ophthalmologists at Guy's and St Thomas' unveiled a portrait of Sir Harold Ridley gifted to the hospital by the Ridley Eye Foundation.
Dr Sancy Low, the consultant ophthalmic surgeon who performed Mr McBean's surgery, said: "The story of Sir Harold Ridley's journey is an incredible reminder of how we can bring light to the world, changing the lives of John, Freda and millions worldwide."
Listen to the best of BBC Radio London on Sounds and follow BBC London on Facebook, X and Instagram. Send your story ideas to hello.bbclondon@bbc.co.uk
Cancer survivor reunited with life-saving optician
Woman, 88, gets bionic eye implant
Hundreds of cataract surgeries in 'Covid catch-up'
Guy's and St Thomas' NHS Foundation Trust
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Corrupt Edinburgh NHS manager jailed for eight years over £6m contracts
Four men have been jailed for a total of 29 years over the awarding of NHS contracts worth £6million. Alan Hush, 68, Adam Sharoudi, 41, Gavin Brown, 48, and Gavin Cox, 60, were convicted by a jury following an investigation at health boards across Scotland. Hush, telecommunications manager at NHS Lothian and then NHS Scotland's video conferencing manager, was sentenced to eight years in jail. READ MORE: Edinburgh man's touching tribute for best pal after his unexpected death at 38 READ MORE: 'Maggots burst from tin of tuna I was about to feed my baby - I can never eat touch it again' Sharoudi and Brown, directors of Ayrshire-based telecommunications firm Oricom Ltd, were imprisoned for eight years and seven years respectively. Cox, who held the post of head of IT and infrastructure at NHS Lanarkshire, will spend six years in prison. Sineidin Corrins, Deputy Procurator Fiscal for Specialist Casework at the Crown Office and Procurator Fiscal Service (COPFS), said: 'This is an outstanding result for justice in Scotland. 'As prosecutors, we have shown an unwavering commitment to pursuing and investigating this matter. This was a betrayal of public trust. 'These four men colluded to create a sophisticated criminal scheme. The public will rightly be shocked by the scale of their criminality. The scale of this offending against our public health service is particularly egregious. 'The systematic abuse of position by public officials, who accepted inappropriate benefits including cash, holidays and entertainment in exchange for contract advantages, strikes at the heart of public trust. 'It serves as a reminder that procurement processes exist to ensure fair competition and value for public money. When these processes are corrupted, all of society bears the cost. 'The prosecutorial journey has been complex and demanding. It required forensic examination of thousands of documents, hundreds of witness statements, and detailed financial analyses to establish the full extent of this criminal activity. Sign up for Edinburgh Live newsletters for more headlines straight to your inbox 'The digital evidence, particularly text messages and emails exchanged between the accused, proved pivotal in exposing the true nature of these arrangements. 'This was a meticulous investigation and one which reflects the enduring partnership working between specialist Crown Office prosecutors, NHS Counter Fraud Services and Police Scotland who worked tirelessly over many years. 'Their unflinching dedication to serving the interests of justice, regardless of complexity or duration, deserves recognition. 'The Crown Office and Procurator Fiscal Service has worked closely with these specialist reporting agencies to ensure justice has been served. 'This case demonstrates clearly that those who indulge in corrupt practices for their own personal gain will be brought to book regardless of the time it takes to bring offenders to justice. Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. 'The Proceeds of Crime proceedings that will follow demonstrate our ongoing commitment to ensuring that crime does not pay and that illicitly obtained funds are recovered where possible.' All four individuals will now be subject to confiscation action under Proceeds of Crime legislation to recover monies illegally obtained. Brown and Sharoudi were also banned from being company directors for 10 years.
Yahoo
3 hours ago
- Yahoo
AI to help end ‘postcode lottery' for vital prostate cancer drug
AI could bring an end to the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, researchers have said. A study has discovered that the technology can identify the patients who will benefit most from a "game changer" drug. Abiraterone, a hormone therapy that blocks testosterone production to prevent the growth of prostate cancer, is approved for NHS use in England for patients with advanced prostate cancer that has spread. However, it is not approved for men newly diagnosed with high-risk prostate cancer that has not yet spread, even though it has been available for these patients in Scotland and Wales for the past two years. The new test, developed by Artera, uses AI to detect features invisible to the human eye on images of tumour samples. The study, led by The Institute of Cancer Research, London, and University College London (UCL), ran the test on biopsy images from more than 1,000 men who took part in the Stampede trial. Patients were given a score of either biomarker-positive or biomarker-negative. Researchers found abiraterone reduced the risk of death among biomarker-positive patients from 17 per cent to 9 per cent. In biomarker-negative patients, the drug cut death risk from 7 per cent to 4 per cent, with researchers suggesting this indicates these men would benefit from standard therapy. Nick James, a professor of prostate and bladder cancer research at The Institute of Cancer Research, London, and consultant clinical oncologist at The Royal Marsden NHS Foundation Trust, is chief investigator of Stampede and co-led the new study. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy. 'Access to this life-extending drug is currently a postcode lottery – with those living in Scotland and Wales able to receive the treatment for free. 'The NHS in England has previously decided that it would be too expensive to offer the drug. Since the patent expired in 2022, abiraterone costs just £77 per pack – compared with the thousands of pounds that new drugs cost. 'Previous research by my team has shown that preventing cancer relapses for these men would save more money than the drug costs to purchase. 'I truly hope that this new research – showing precisely who needs the drug to live well for longer – will lead to NHS England reviewing their decision not to fund abiraterone for high-risk prostate cancer that has not spread.' Prof James also highlighted that while abiraterone can have 'spectacular' results, it does have side effects. 'Abiraterone has already hugely improved the outlook for hundreds of thousands of men with advanced prostate cancer,' he said. 'We know that for many men with cancer that has not yet spread, it can also have spectacular results. 'But it does come with side effects and requires additional monitoring for potential issues with high blood pressure or liver abnormalities. 'It can also slightly increase the risk of diabetes and heart attacks, so knowing who is most likely to benefit is very valuable.' Experts hope the findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, may lead to a change in the availability of abiraterone in England. Prof Kristian Helin, chief executive of The Institute of Cancer Research, said the drug has been a 'game changer for treatment of prostate cancer'. 'Alongside our mission to find smarter, kinder treatments, we must ensure we are matching the right drugs to the right patients,' he added. 'This research, using artificial intelligence, provides an innovative route to testing prostate cancer patients to determine their treatment. 'I hope that this can be implemented so that all men with prostate cancer who will benefit from abiraterone can do so.' Dr Matthew Hobbs, director of research at Prostate Cancer UK, said: 'Prostate Cancer UK has been calling on the UK Government to approve this life-saving, cost-effective drug for over two years. 'These exciting results suggest a way to make this an even more cost-effective approach. 'We therefore echo the researchers' urgent call for abiraterone to be made available to those men whose lives it can save – men who, thanks to this research, we can now identify more precisely than ever before.'
Yahoo
3 hours ago
- Yahoo
Funding Gavi is the simplest financial decision facing Keir Starmer. He must get it right
When he announced he was cutting international cooperation and aid to its lowest level on record, Keir Starmer promised he would protect global health. He is now about to take a decision that will show how serious he was. Will he maintain the UK's support for the global vaccine alliance, Gavi, which has prevented an estimated 18 million deaths since its inception in 2000? In the view of Save the Children and more than 150 other organisations around the world, it is critical that he does. Gavi has been one of the most effective investments in public health in modern history. In the last 25 years, the alliance has helped immunise more than a billion children. Gavi supports the rollout of vaccines for everything from measles to polio to Ebola. In doing so, it not only saves lives but builds up national health systems, strengthens pandemic preparedness and helps protect us all – everywhere including Britain – from the spread of infectious disease. Five years ago, through the Covid-19 pandemic, we witnessed that when it comes to health, nobody is safe until everyone is safe. Gavi's purpose is to shield us from the re-emergence of pandemics and lethal but preventable diseases. The fact that it is struggling to secure enough money to continue its critical mission tells us a lot about the geo-political climate today and the false instinct to draw back from international cooperation to solve global problems. Vaccination is one of the most cost-effective health interventions known to mankind. The World Health Organization (WHO) estimates the return on routine vaccinations at $54 for every $1 invested. You'll be hard-pressed to find a more attractive investment proposition; and that's before you take account of the human factor. Anyone who has met a mother mourning a child who could have been saved by a routine jab or seen toddlers gasping for breath because their measles has turned into pneumonia, will know what I mean. I understand it can feel difficult to back aid in times of economic crisis, budget deficits and a struggling NHS here at home. When it comes to Gavi and global health security, however, the benefits so outweigh the costs that any vacillation seems incomprehensible. Infectious diseases know no borders, and the cost comes home to Britain. In 2023-24, more than 20 per cent of secondary care bed days in the NHS were attributable to infectious disease or infections. The cost to the NHS was £5.9 billion. Gavi's role in supporting routine vaccination and its stockpiles of vaccines against killers such as Ebola, cholera and yellow fever represent our first line of defence against future pandemics and the terrible costs counted in ruined lives and devastating economic damage. Some say governments in the Global South could, and maybe should, buy their own vaccines. They ask why British taxpayers should pay for jabs for African arms. This misses an important point: vaccine markets, like many essential commodities, are global. If every country did its own procurement, the poorest – those with the lowest bargaining power – would immediately be priced out of essential, life saving vaccines. Perhaps the most important thing Gavi has done in the last 30 years is to shape this market. By guaranteeing the purchase of hundreds of millions of vaccines over many years, Gavi has enabled pharma companies to manufacture many more doses and, through economies of scale, do it much more cheaply than would otherwise be the case. It has also enticed other firms to enter the fray and compete. Witness the Serum Institute of India, which played a major role in supplying Covid-19 vaccines during the pandemic and has now become a vaccine manufacturing giant. And Gavi works with countries to 'graduate' so that they pay for an increasingly large share of their own vaccines as they become richer, thereby ensuring that aid-funded doses go to the poorest and most vulnerable countries. The UK, as a founding member, has helped Gavi become the world-changing alliance it is today. Our partnership has put British scientific leadership in the global spotlight. From 18 million doses of ground-breaking malaria vaccines that are already saving lives in Africa to digital biometric identification and record-keeping that are transforming health systems in Ghana, Gavi links UK scientists and innovators with partner governments in the global South. At Save the Children, we're working with national governments and local communities – for example in Malawi where a recent cholera outbreak killed more than 1,700 people – to make sure children are protected from deadly and debilitating illness. With our private sector partner GSK, we are targeting millions of 'zero-dose' children who are completely unvaccinated in Nigeria and Ethiopia. In war-torn Sudan, we are transporting vials into a country whose health services are shattered. All this would be immeasurably harder to do without Gavi ensuring that vaccines are made affordably in large enough quantities for the most vulnerable populations. To keep up UK funding of Gavi is one of the most straightforward decisions this government must make. I know a bargain when I see one. I hope Keir Starmer will too. Moazzam Malik is chief executive of Save the Children UK Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
